ライフサイエンスコーパス: antitumor efficacy

1 the tumor microenvironment, eliciting potent antitumor efficacy.

2 CTL combined with CTLA4 blockade might boost antitumor efficacy.

3 cargoes in tumor cells, leading to enhanced antitumor efficacy.

4 elf-tumor antigen positively correlated with antitumor efficacy.

5 rapalogs-mediated immune modulation on their antitumor efficacy.

6 rapy of lung cancer with improved safety and antitumor efficacy.

7 therapy and chemotherapy to receive superior antitumor efficacy.

8 early exhaustion of CAR T cells that limits antitumor efficacy.

9 al small-molecular drug, leading to enhanced antitumor efficacy.

10 fic chemosensitivity patterns and to monitor antitumor efficacy.

11 phery to mild hyperthermia and increases RFA antitumor efficacy.

12 een by alpha-GalCer that might attenuate its antitumor efficacy.

13 channel-modulating agents have demonstrated antitumor efficacy.

14 5TNFR mitigates TNF toxicity without loss of antitumor efficacy.

15 lockade synergized with vaccine in eliciting antitumor efficacy.

16 MYCi with anti-PD-1/PD-L1 therapy to enhance antitumor efficacy.

17 e CD27 (mCD27) with agonist mAbs can mediate antitumor efficacy.

18 of transferred T cells can lead to improved antitumor efficacy.

19 ic T cells, with trafficking correlated with antitumor efficacy.

20 its poor bioavailability in vivo limits its antitumor efficacy.

21 IDO targeting for ethyl pyruvate to achieve antitumor efficacy.

22 immunization strategies to achieve enhanced antitumor efficacy.

23 ivalent to those associated with preclinical antitumor efficacy.

24 ncer, beta-lap synergized with IR to promote antitumor efficacy.

25 n-7 receptor, heightened apoptosis, and poor antitumor efficacy.

26 ed enhancement of CD8+ T-cell activation and antitumor efficacy.

27 repeats), has significant antiangiogenic and antitumor efficacy.

28 nduce systematic immune responses and superb antitumor efficacy.

29 irect intracerebral inoculation in mice, and antitumor efficacy.

30 s that target multiple pathways for enhanced antitumor efficacy.

31 of CD25(hi) T cells did not further improve antitumor efficacy.

32 th a controlled loading that achieved better antitumor efficacy.

33 TME might limit both T cell persistence and antitumor efficacy.

34 ombination immunotherapies to pursue maximal antitumor efficacy.

35 l of tumor-bearing mice and showed promising antitumor efficacy.

36 This novel approach significantly improved antitumor efficacy.

37 rine association and resulted in compounding antitumor efficacy.

38 autoimmune side effects without compromising antitumor efficacy.

39 tions offers a promising strategy to enhance antitumor efficacy.

40 duced neutropenia and anemia while retaining antitumor efficacy.

41 uppressive immune-modulating agents (IMs) on antitumor efficacy.

42 ting that sequential schedules could improve antitumor efficacy.

43 mcitabine as an optimal protocol to maximize antitumor efficacy.

44 ity, which has been associated with superior antitumor efficacy.

45 and adaptive immunity will result in better antitumor efficacy.

46 lue of (89)Zr-bevacizumab PET for everolimus antitumor efficacy.

47 tor T-cell responses, to augment therapeutic antitumor efficacy (66% reduction in tumor growth; P = .

48 od mononuclear cells or T cells enhanced the antitumor efficacy achieved by the parental counterpart.

49 and clinical samples; we therefore examined antitumor efficacy across a panel of five PI3K inhibitor

50 nucleotide-bearing nanoparticles facilitate antitumor efficacy after systemic intravenous (i.v.) adm

51 ped a mouse CD19-specific CAR to investigate antitumor efficacy against a syngeneic B cell lymphoma c

52 istence following ACT, resulting in superior antitumor efficacy against established solid and hematol

53 standard chemotherapy drug for GBM increased antitumor efficacy against glioblastoma in experimental

54 ilencing with RIG-I signaling confers potent antitumor efficacy against pancreatic cancer by breaking

55 M1-like phenotype, and significantly improve antitumor efficacy against poorly immunogenic TNBCs.

56 rophic for leu-arg, is tumor-seeking and has antitumor efficacy against the major types of cancer.

57 combined with radiation, ABDNAZ accentuated antitumor efficacy along with the therapeutic index.

58 Antitumor efficacy analyses in mice bearing subcutaneous

59 ases, as well as pan-Aurora inhibitors, show antitumor efficacy and are now under clinical investigat

60 reprogramming of T cells to achieve superior antitumor efficacy and even complete cures.

61 the hybrid PeptiCRAd significantly enhanced antitumor efficacy and induced TT-specific, CD40 ligand-

62 geneic mouse tumor models, 1F5 showed potent antitumor efficacy and induction of protective immunity,

63 Similar in vivo antitumor efficacy and intratumoral CD8(+)/regulatory T

64 ocal heat that has already shown substantial antitumor efficacy and is in human trials.

65 tly into tumor cells with consequent greater antitumor efficacy and less systemic toxicity.

66 xel (PTX)-loaded OA02-NPs exhibited superior antitumor efficacy and lower systemic toxicity profile i

67 characterize a human IL-2 mutant with higher antitumor efficacy and lower toxicity than wild type hum

68 ta demonstrate that XmAbCD40 displays potent antitumor efficacy and merits further evaluation for the

69 (DOX)-loaded SNP (SNP/DOX) shows significant antitumor efficacy and nearly eradicates the tumor, subs

70 nanochemistry for targeting PI3K to enhance antitumor efficacy and potentially overcome these limita

71 Synergistic antitumor efficacy and prolonged survival were noted in

72 owed that ibrutinib could improve CAR T cell-antitumor efficacy and reduce cytokine release syndrome

73 us at the tumor site can further enhance the antitumor efficacy and reduce potential off-target effec

74 odel overexpressing GLUT1, compound 2 showed antitumor efficacy and selective uptake in tumors with n

75 combination is expected to have synergistic antitumor efficacy and significant potential for the tre

76 These effects were associated with increased antitumor efficacy and survival as compared with PI103 a

77 ibitor, alpha-PD-1 Ab, resulting in enhanced antitumor efficacy and survival.

78 ave yielded promising, yet limited, signs of antitumor efficacy and therefore need to be improved for

79 Antitumor efficacy and toxicity were examined through a

80 ng nelfinavir might experience both enhanced antitumor efficacy and unexpected adverse toxicity given

81 mitigated antigen escape, displayed enhanced antitumor efficacy, and improved animal survival.

82 o the albumin carrier and achieves excellent antitumor efficacy, and it has the potential to greatly

83 To improve its antitumor efficacy, and offer strategies for its combina

84 SERD), exhibiting good oral bioavailability, antitumor efficacy, and SERD activity in vivo.

85 Despite clear antitumor efficacy, antiangiogenic therapy did not alter

86 ct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate.

87 on of bortezomib and SP1017 exerted enhanced antitumor efficacy as compared to bortezomib alone, dela

88 unization with DNA and Ad5 produced superior antitumor efficacy associated with increased TCR avidity

89 ation from 30 to 60 mg/kg sorafenib improved antitumor efficacy but worsened survival due to excessiv

90 The established role of CD8(+) T cells in antitumor efficacy, but CD4(+) T cells in autoimmunity,

91 idity TCRs can be improved to increase their antitumor efficacy, but conventional saturation mutagene

92 gens in solid malignancies where it exhibits antitumor efficacy, but its clinical utility for treatin

93 veloped system showed significantly enhanced antitumor efficacy by H(2)O(2) production and prodrug ac

94 addition, Tf-Pen liposomes showed excellent antitumor efficacy by regressing ~90% of tumor in mice b

95 yde interacts with anthracyclines to enhance antitumor efficacy, bypass resistance mechanisms, improv

96 In vivo, the Prot-FOLR1-TCB mediates antitumor efficacy comparable to the parental FOLR1-TCB

97 espite having a shorter serum half-life, had antitumor efficacy comparable with equimolar v-mab; 22-2

98 F-5412 with sunitinib significantly improved antitumor efficacy compared with either agent alone.

99 o, we show enhanced expansion and CAR T cell antitumor efficacy, culminating in improvement in surviv

100 quely safe profile of induced cytokines, and antitumor efficacy demonstrated in a number of animal mo

101 was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of

102 Unexpectedly, despite the improved antitumor efficacy engendered by TMZ-induced lymphopenia

103 We demonstrate superior antitumor efficacy for IgE compared with an otherwise id

104 These results establish proof-of-concept antitumor efficacy for tankyrase inhibitors in APC-mutan

105 In vivo antitumor efficacy for the anti-HER2 ADCs in Founder 5 w

106 with enhanced safety, pharmacokinetics, and antitumor efficacy for the specific treatment of NSCLC t

107 -CTLA4 DVD provides an avenue for uncoupling antitumor efficacy from immunotherapy-induced toxicities

108 strategies attempts to decouple the observed antitumor efficacy from the on-target liver toxicity.

109 in well-characterized mouse models in which antitumor efficacy has been shown; inhibiting only late

110 r monoclonal antibodies to increase ADCC and antitumor efficacy, have been initiated.

111 erm PDK1 knockdown revealed a lack of potent antitumor efficacy in 3 different mouse models of PTEN-d

112 rgeting these nodes concurrently resulted in antitumor efficacy in a majority of cetuximab-resistant

113 N inhibits glutamine metabolism and provides antitumor efficacy in a murine model of glioblastoma, al

114 mice and demonstrated superior single-agent antitumor efficacy in a PPC-1 mouse xenograft model.

115 d show that the nanoparticle yields improved antitumor efficacy in a preclinical human melanoma xenog

116 and also demonstrated superior single-agent antitumor efficacy in a prostate cancer mouse xenograft

117 A-BN-PRO and resulted in a trend of improved antitumor efficacy in a PSA-expressing tumor model.

118 fortunately, intravesical IL-12 did not show antitumor efficacy in a recent clinical study of patient

119 NC280, a cMET inhibitor, resulted in durable antitumor efficacy in a xenograft model that initially d

120 nd an orally bioavailable compound (32) with antitumor efficacy in ALK-driven xenografts in mouse mod

121 y, sustained multi-drug exposure, and potent antitumor efficacy in an ES-2-luc, ovarian cancer i.p. x

122 endent gene expression in vivo, demonstrates antitumor efficacy in an MV-4-11 mouse xenograft model,

123 Furthermore, dinaciclib revealed in vivo antitumor efficacy in an orthotopic xenograft mouse mode

124 xcellent activity in vitro and in vivo, with antitumor efficacy in both subcutaneous and orthotopic x

125 is-platinum nanoparticle results in enhanced antitumor efficacy in breast cancer as compared with whe

126 its dose escalation over Taxol(R), enhancing antitumor efficacy in breast, lung and ovarian cancers.

127 may lead to enhanced and sustained clinical antitumor efficacy in CRCs harboring the BRAF(V600E) mut

128 lly, the CH-NPs showed significantly greater antitumor efficacy in EG.7 and TC-1 tumor-bearing mice c

129 revents the PIP3 rebound and induces greater antitumor efficacy in HER2-amplified and PIK3CA mutant c

130 tudies revealed that FL118 exhibits superior antitumor efficacy in human tumor xenograft models in co

131 IFNgamma was implicated, given a lack of antitumor efficacy in IFNgamma(-/-) mice.

132 encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models.

133 characteristics of the drug, with equivalent antitumor efficacy in LNCaP xenografts at 1/3 the dose o

134 BRAF inhibitors have demonstrated antitumor efficacy in melanoma therapy but have also bee

135 eover, in vivo peptide administration showed antitumor efficacy in mice bearing Hepa129 or TC1 tumor

136 This prodrug leads to superior antitumor efficacy in mice compared to HMR 1826, a well-

137 eting the constant region of CD44 that shows antitumor efficacy in mice implanted with CD44-expressin

138 d donor cell polyfunctionality, and enhanced antitumor efficacy in multiple immunocompetent mouse tum

139 ion of these compounds would yield increased antitumor efficacy in multiple myeloma and glioblastoma

140 icles exhibit significantly enhanced in vivo antitumor efficacy in murine 4T1 breast cancer and in K-

141 mall cell lung cancer (SCLC) cell lines, and antitumor efficacy in patient-derived xenograft (PDX) SC

142 , navitoclax (ABT-263), have shown promising antitumor efficacy in preclinical and early clinical stu

143 t conditions, based on modeling, for maximum antitumor efficacy in terms of drug-light interval (DLI)

144 noparticles exhibited significantly improved antitumor efficacy in terms of tumor growth delay in bre

145 armacokinetic (PK) properties and remarkable antitumor efficacy in the BRCA1 mutant MX-1 breast cance

146 duced serious diarrhea while maintaining the antitumor efficacy in tumor-bearing mice.

147 AUY922 exhibits antitumor efficacy in vitro and in vivo for EAC, suggest

148 lization, cytotoxicity, tumor targeting, and antitumor efficacy in vitro and in vivo over its nonsens

149 be synergistic with phototherapy to improve antitumor efficacy in vitro and in vivo, offering a new

150 th 17-AAG and doxorubicin exhibited superior antitumor efficacy in vivo in an ErbB2-driven xenograft

151 Most significantly, CMP-L-CA4 had better antitumor efficacy in vivo than its noncleavable (NC) an

152 mitter (125)I-DCIBzL yielded highly specific antitumor efficacy in vivo, suggesting promise for treat

153 nd interleukin (IL)-7/IL-15 was required for antitumor efficacy in vivo.

154 onality by means of restimulation ex vivo or antitumor efficacy in vivo.

155 ity in vitro and can synergistically improve antitumor efficacy in vivo.

156 agonist to the tumor site can contribute to antitumor efficacy, in the context of adoptive T-cell im

157 In terms of antitumor efficacy, iRGD coadministration significantly

158 tor I induction by IP6 plays any role in its antitumor efficacy is unknown.

159 e immune checkpoint blockade leads to potent antitumor efficacy, it also leads to immune-related adve

160 the CD40L(+) CAR T cells displayed superior antitumor efficacy, licensed antigen-presenting cells, e

161 In severe combined immunodeficient mice, the antitumor efficacies of C1 and C2 were greater toward su

162 The antitumor efficacy of (211)At- 6: was evaluated in mice

163 The antitumor efficacy of (212)Pb-L2 supports the correspond

164 Antitumor efficacy of (212)Pb-L2 was evaluated in PSMA(+

165 This study aimed to explore the antitumor efficacy of (67)Cu-CuSarTATE in a preclinical

166 ility of the probes to predict the potential antitumor efficacy of 2'-deoxy-2',2'-difluorocytidine (g

167 In this study, we investigated the antitumor efficacy of a CXCR4 antagonist expressed by on

168 cally, we analyzed how rapamycin affects the antitumor efficacy of a human papilloma virus E7 peptide

169 These results show the in vitro and in vivo antitumor efficacy of a prototype small molecule inhibit

170 Overall, our results argued that the antitumor efficacy of a virally based transgene therapeu

171 DC1s played a critical role in expansion and antitumor efficacy of adoptively transferred CD8(+) T ce

172 CD40, CD70, and CD80/CD86, in expansion and antitumor efficacy of adoptively transferred in vitro-pr

173 ignificantly increased the expansion and the antitumor efficacy of adoptively transferred pmel-1 CD8(

174 e found that TLR/CD40-mediated expansion and antitumor efficacy of adoptively transferred tumor-speci

175 hat targeting eEF-2 kinase may reinforce the antitumor efficacy of Akt inhibitors such as MK-2206.

176 Here, we evaluated the antitumor efficacy of AMD3100 and anti-PD-1 (alphaPD-1)

177 for a combinatorial approach to enhance the antitumor efficacy of an OV, suggesting a strategy to im

178 SLR14 also greatly improved antitumor efficacy of anti-PD1 antibody over single-agen

179 ased sBCMA in peripheral blood, and improved antitumor efficacy of BCMA-targeted CAR T-cell therapy.

180 ockdown of NAC1 expression can reinforce the antitumor efficacy of bevacizumab, an inhibitor of angio

181 We observed an outstanding antitumor efficacy of both (+/-)-ETP 2 and meso-ETP 2 in

182 ation of fatty acids (etomoxir) enhanced the antitumor efficacy of c-MET inhibition.

183 t and depleting properties contribute to the antitumor efficacy of CD27-targeted immunotherapy, and m

184 7-DMAG-based "pulse" therapy may improve the antitumor efficacy of CD8(+) T effector cells reactive a

185 mice inhibits tumor growth and enhances the antitumor efficacy of cisplatin chemotherapy.

186 depletion of Akt ubiquitination enhances the antitumor efficacy of cisplatin in vitro and in vivo.

187 4, a key mediator of autophagy, enhanced the antitumor efficacy of cisplatin.

188 the chemical inhibitor brusatol enhanced the antitumor efficacy of cisplatin.

189 Finally, the antitumor efficacy of complex 1 was validated in the mur

190 ibe initial animal studies demonstrating the antitumor efficacy of compound 5 in vivo.

191 The synergistic antitumor efficacy of cotransferred activated B effector

192 of indoleamine 2,3-dioxygenase (IDO) on the antitumor efficacy of CTLA-4 blockade.

193 or function of CD8 TILs and thus improve the antitumor efficacy of current cancer vaccines.

194 Investigations in vivo showed equivalent antitumor efficacy of deoxynyboquinone to beta-lapachone

195 potential effects of sildenafil on improving antitumor efficacy of DOX in prostate cancer.

196 The antitumor efficacy of Doxil(R) is hindered by the poor r

197 her MyD88-dependent signaling may reduce the antitumor efficacy of EGFRIs in HNSCC.

198 6 pathway may be responsible for the reduced antitumor efficacy of erlotinib and other EGFRIs, and bl

199 e the potential of disulfiram to enhance the antitumor efficacy of external-beam gamma-irradiation an

200 This study evaluated the antitumor efficacy of farnesylthiosalicylic acid (FTA) l

201 likely, limit the protective and therapeutic antitumor efficacy of gamma9delta2T cells.

202 IDO1 inhibitor enhanced antitumor efficacy of GVAX in a murine model of PDACs.

203 of combination therapy to further boost the antitumor efficacy of ICB.

204 important obstacle to the evaluation of the antitumor efficacy of immunomodulator Abs in syngeneic m

205 ta pathway is a promising way to improve the antitumor efficacy of ionizing radiation and warrants cl

206 ating peptide improves tumor selectivity and antitumor efficacy of IP pro-apoptotic NWs.

207 events intestinal toxicity and maintains the antitumor efficacy of irinotecan.

208 eristics of tumors of origin to evaluate the antitumor efficacy of JQ1.

209 or, resulting in a marked improvement in the antitumor efficacy of lv immunization.

210 or immunotherapy and may explain the limited antitumor efficacy of lv immunization.

211 in vitro and in vivo, resulting in enhanced antitumor efficacy of lv immunization.

212 n of TNFR1 on lung cancer cells impaired the antitumor efficacy of MEKi, whereas the administration o

213 gs have been limited until recently, and the antitumor efficacy of most cancer immunotherapies still

214 , while Fas signaling blockade preserved the antitumor efficacy of naive cells within mixed populatio

215 We demonstrate that the antitumor efficacy of nanoparticle is much superior to t

216 r in vitro as well as in vivo studies showed antitumor efficacy of NVP-LDE225 in combination with bor

217 The dual mechanism of action and robust antitumor efficacy of PF-5412 support its clinical devel

218 G2 inhibitors would effectively increase the antitumor efficacy of purine nucleosides by blocking dru

219 c antigen receptors (CARs) have improved the antitumor efficacy of redirected T cells.

220 This study aims at characterizing the antitumor efficacy of sesamol and unveiling the importan

221 The antitumor efficacy of some taccalonolides, which stabili

222 Antitumor efficacy of subsequently infused 19-28z(+) eff

223 severely immunodeficient mice to assess the antitumor efficacy of systemic NBP treatments when combi

224 Antitumor efficacy of T cells depended on the presence o

225 t pathways of nuclear import that affect the antitumor efficacy of taxanes, suggesting a mechanistic

226 Antitumor efficacy of TCR-transduced T cells was confirm

227 d by a therapeutic antibody can heighten the antitumor efficacy of the antibody.

228 rimary aim of this study was to evaluate the antitumor efficacy of the bromodomain inhibitor JQ1 in p

229 Itraconazole significantly enhanced the antitumor efficacy of the chemotherapeutic agent cisplat

230 oyed to investigate mechanisms of action and antitumor efficacy of the combination.

231 of CD4 or CD8 T cells completely eliminated antitumor efficacy of the lymphodepletion/anti-PD-L1 the

232 Further, in vivo antitumor efficacy of the MSLN-TTC in combination with A

233 Further, we evaluated the antitumor efficacy of the MSLN-TTC in combination with D

234 The antitumor efficacy of the therapeutic 47-LDA-Fcgamma2a-D

235 The antitumor efficacy of this anti-HER2-Rae-1beta fusion pr

236 The antitumor efficacy of topotecan, (131)I-MIBG, and (131)I

237 ork provides direct evidence for the in vivo antitumor efficacy of TRAIL being proportional to system

238 Antitumor efficacy of TRAILPEG with tumor-homing sensiti

239 Despite intensive effort, the antitumor efficacy of tumor vaccines remains limited in

240 sed several murine cancer models to test the antitumor efficacy of undifferentiated monocytes loaded

241 Methods: The antitumor efficacy of various doses of (67)Cu-CuSarTATE

242 neutralizing anti-VSV antibodies negate the antitumor efficacy of VSV, a concern for repeat VSV admi

243 ide, and hydroxyl radicals, to afford superb antitumor efficacy on mouse models of breast and colon c

244 ggested by previous studies to have superior antitumor efficacy on various solid tumors.

245 M demonstrated dramatically enhanced in vivo antitumor efficacy over single treatment on nude mice be

246 ectives were to assess safety, tolerability, antitumor efficacy, pharmacokinetics, and pharmacodynami

247 ctor cells that display reduced survival and antitumor efficacy postinfusion.

248 ma was well tolerated and produced increased antitumor efficacy relative to the respective monotherap

249 in vivo are limited persistence and reduced antitumor efficacy, relative to CD8(+) T cells with a ce

250 Maximal antitumor efficacy required four components: a tumor-ant

251 Antitumor efficacy required stringent Treg depletion com

252 erstanding of the molecular determinants for antitumor efficacy resulting from RAF pathway inhibition

253 Affinity-tuned cells exhibited robust antitumor efficacy similar to high-affinity cells, but s

254 Targeted type I interferon elicits powerful antitumor efficacy, similar to wild-type IFN, but withou

255 In vivo antitumor efficacy studies in human prostate (PC-3) and

256 Antitumor efficacy studies in melanoma-bearing mice demo

257 In vivo antitumor efficacy studies using mice inoculated with KB

258 However, antitumor efficacy study of beta-lap-dC3 micelles agains

259 -induced CD8(+) T-cell immunity and improved antitumor efficacy, suggesting manipulating beta-catenin

260 PF-5412 displayed robust and dose-dependent antitumor efficacy superior to that observed with IgG1/w

261 n was obtained by 20, which exhibited higher antitumor efficacy than 3 in PTEN-negative cancer cells

262 of B16F10 melanoma, Cim-F-alb showed higher antitumor efficacy than Abraxane at the same dose.

263 -VEGF-A antibodies did not result in greater antitumor efficacy than anti-VEGF-A monotherapy.

264 rgeted therapies, such as less-than-expected antitumor efficacy that may arise from compensatory incr

265 ibute to more intense signaling and superior antitumor efficacy that they display compared to third-g

266 th acceptable toxicity and promising durable antitumor efficacy that warrant further testing in a ran

267 ough blockade of both CD73 and A2AR enhances antitumor efficacy through distinct mechanisms.

268 peutic approach for pancreatic cancer having antitumor efficacy through modulation of the immune supp

269 tial immunization with DNA and Ad5 maximized antitumor efficacy through TCR avidity enhancement, it p

270 ichia coli by the disk diffusion method, and antitumor efficacy toward the HeLa cell-derived tumor sp

271 ics and in vivo pharmacokinetics that define antitumor efficacy under intermittent dosing conditions.

272 atory target and to address the mechanism of antitumor efficacy using different IgG isotypes of 1F5 i

273 Antitumor efficacy was demonstrated for (E1)-3s coadmini

274 Nonetheless, significant antitumor efficacy was documented after anti-DR5 deliver

275 A-PLGA were engineered and their synergistic antitumor efficacy was evaluated for targeted delivery i

276 use PDA xenografts (+MUC1 or MUC1 null), and antitumor efficacy was further improved when the virus w

277 -4 knock-in mouse lacking FcgammaR function, antitumor efficacy was observed by blocking murine CTLA-

278 This increased antitumor efficacy was observed in several experimental

279 Antitumor efficacy was quantified in vivo using 4T1 brea

280 Antitumor efficacy was significantly abrogated on blocka

281 In vivo antitumor efficacy was tested in nude mice bearing PSMA+

282 o determine the mechanisms of chNKG2D T cell antitumor efficacy, we analyzed how chNKG2D T cells alte

283 heir intracellular domains and their in vivo antitumor efficacy, we found that only second-generation

284 ics (PKs), pharmacodynamics, and preliminary antitumor efficacy were assessed in a phase I study of M

285 Antiangiogenesis and antitumor efficacy were associated with disrupted co-loc

286 ignificantly enhances its immunogenicity and antitumor efficacy when administered after chemotherapy.

287 decreased human vessel density and improved antitumor efficacy when combined with bevacizumab (anti-

288 Compound 50 also showed excellent in vivo antitumor efficacy when dosed orally in an A2780 ovarian

289 Compound 25b exhibited significant in vivo antitumor efficacy when dosed orally in an ALK-positive

290 rime or prime-boost regimens correlated with antitumor efficacy, whereas T cell number and cytokine p

291 erent valencies did not significantly affect antitumor efficacy, whereas the presence of an Fc domain

292 erties were optimized on plasma exposure and antitumor efficacy which led to the identification of ad

293 les in the clinic, MYD1-72 achieved superior antitumor efficacy while displaying no toxicity.

294 murine monocytes and results in an enhanced antitumor efficacy with dl309 in vivo.

295 lso exhibited at least 5-fold enhancement in antitumor efficacy with only 40% of the drug employed du

296 f CA4-NPs and MMP9-DOX-NPs exhibits enhanced antitumor efficacy with reduced systemic toxicity compar

297 We then explored the antitumor efficacy with survival advantage following for

298 f ATR have been reported showing significant antitumor efficacy, with most advanced ones entering cli

299 ved pharmacokinetic properties and excellent antitumor efficacy, with significantly reduced tumor gro

300 idity enhancement eliminated GUCY2C-specific antitumor efficacy, without affecting responding T cell